Table 1.
Variable | Entire group (n = 126) |
PTTG1 expression |
χ 2 | p-value | |
---|---|---|---|---|---|
Low expression (n = 63) | High expression (n = 63) | ||||
Age at surgery (y, median ± SD) | 57.0 ± 11.7 | 57.0 ± 13.2 | |||
BMI (kg/m2, median ± SD) | 22.9 ± 3.4 | 22.5 ± 3.2 | |||
Tumour size (cm, median ± SD) | 4.0 ± 2.5 | 5.0 ± 3.0 | |||
OS time (month, median ± SD) | 54.0 ± 35.6 | 42.0 ± 35.2 | |||
PFS time (month, median ± SD) | 54.0 ± 38.7 | 36.0 ± 39.7 | |||
Sex (n, %) | 0.904 | .342 | |||
Male | 85, 67.5% | 45, 71.4% | 40, 63.5% | ||
Female | 41, 32.5% | 18, 28.6% | 23, 36.5% | ||
Laterality (n, %) | 1.581 | .209 | |||
Left | 71, 56.3% | 39, 61.9% | 32, 50.8% | ||
Right | 55, 43.7% | 24, 38.1% | 31, 49.2% | ||
Tumour type | 0.293 | .588 | |||
Type 1 pRCC | 53, 42.1% | 28, 44.4% | 25, 39.7% | ||
Type 2 pRCC | 73, 57.9% | 35, 55.6% | 38, 60.3% | ||
T stage (n, %) | 3.889 | .049 | |||
T1–T2 | 90, 71.4% | 50, 79.4% | 40, 63.5% | ||
T3–T4 | 36, 28.6% | 13, 20.6% | 23, 36.5% | ||
N stage (n, %) | 6.038 | .014 | |||
N0 | 101, 80.2% | 56, 88.9% | 45, 71.4% | ||
N1 | 25, 19.8% | 7, 11.1% | 18, 28.6% | ||
M stage (n, %) | 5.704 | .017 | |||
M0 | 99, 78.6% | 55, 87.3% | 44, 69.8% | ||
M1 | 27, 21.4% | 8, 12.7% | 19, 30.2% | ||
AJCC stage (n, %) | 7.327 | .007 | |||
I–II | 73, 57.9% | 44, 69.8% | 29, 46.0% | ||
III–IV | 53, 42.1% | 19, 30.2% | 34, 54.0% | ||
Furhman grade (n, %) | 7.966 | .005 | |||
1–2 | 27, 21.4% | 20 , 31.7% | 7, 11.1% | ||
3–4 | 99, 78.6% | 43, 68.3% | 56, 88.9% | ||
ICB response (n = 62) | n = 19 | n = 43 | 3.99 | .046 | |
PD/SD | 41, 66.1% | 16, 84.2% | 25, 58.1% | ||
PR/CR | 21, 33.9% | 3, 15.8% | 18, 41.9% |
pRCC: papillary renal cell carcinoma; FUSCC: Fudan University Shanghai Cancer Centre; BMI: body mass index; AJCC: American Joint Committee on Cancer; ICB: immune checkpoint blockade. *p-value less than .05 was considered as statistically significant and marked in bold.